This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
TT, HSIC, SONY, LYV and ERII have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2023.
Humana (HUM) Exits Business Line to Focus More on Core Units
by Zacks Equity Research
Humana (HUM) will depart from the Employer Group Commercial Medical Products business so that it can invest more funds to grow its core Insurance business lines.
Best Momentum Stocks to Buy for February 23rd
by Zacks Equity Research
HSIC, IBP and SONY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 23, 2023.
Best Growth Stocks to Buy for February 23rd
by Zacks Equity Research
HSIC, LW and ELF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2023.
Best Value Stocks to Buy for February 23rd
by Zacks Equity Research
HSIC and SONY made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2023.
3 Reasons Growth Investors Will Love Henry Schein (HSIC)
by Zacks Equity Research
Henry Schein (HSIC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should Value Investors Buy Henry Schein (HSIC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Henry Schein (HSIC) Q4 Earnings In Line, Gross Margin Up
by Zacks Equity Research
Growth in Technology and Value-added Services and the Medical segment drove Henry Schein's (HSIC) Q4 revenues.
Henry Schein (HSIC) Matches Q4 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) dental business is likely to have gained in Q4 from the acquisition of Midway Dental.
Henry Schein (HSIC) Expands Dental Offerings With New Pact
by Zacks Equity Research
Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.
Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down
by Zacks Equity Research
Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.
Henry Schein (HSIC) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0.88% and 4.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.
Why Is Henry Schein (HSIC) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
Henry Schein (HSIC) Beats Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.57% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Henry Schein (HSIC) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merit Medical (MMSI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 25.86% and 4.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?